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Abstract: Sarcomas are deadly malignant tumors of mesenchymal origin occurring at all ages.
The expression and function of the membrane-type matrix metalloproteinase MMP14 is closely
related to the mesenchymal cell phenotype, and it is highly expressed in most sarcomas. MMP14
regulates the activity of multiple extracellular and plasma membrane proteins, influencing cell–cell
and cell–extracellular matrix (ECM) communication. This regulation mediates processes such as
ECM degradation and remodeling, cell invasion, and cancer metastasis. Thus, a comprehensive
understanding of the biology of MMP14 in sarcomas will shed light on the mechanisms controlling
the key processes in these diseases. Here, we provide an overview of the function and regulation of
MMP14 and we discuss their relationship with clinical and pre-clinical MMP14 data in both adult
and childhood sarcomas.
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1. Introduction
Sarcomas are a heterogeneous and deadly group of mesenchymal malignancies that are relatively
rare, accounting for <1% of all adult malignancies, but they are the fourth most common childhood
cancer type [1]. Sarcomas can occur at all sites of the body and are generally classified as sarcomas
of the soft tissue or bone (i.e., osteosarcoma) depending on the connective tissue they originate from.
However, the identification of molecular and histological traits of the different subtypes rather than the
tissue of origin are stronger parameters for the classification of sarcomas [2]. Thus, understanding the
biological mechanisms behind these histological characteristics will be essential for improving their
clinical management.
The crosstalk between the surrounding tumor microenvironment (TME) and sarcoma cells plays
a central role in tumor initiation and progression, affecting patient prognosis [3]. The extracellular matrix
(ECM), including fibrillar collagens as the major connective tissue components, is often aberrantly
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regulated in sarcomas, and the increased matrix deposition, crosslinking, and degradation are all
characteristics that make sarcomas aggressive tumors [4–6]. Neighboring cells such as endothelial
cells, immune cells and cancer associated fibroblasts represent the other main component of the
TME. These cells are also involved in and affected by ECM remodeling, altogether contributing to
sarcoma metastasis and response to therapies [7,8]. Understanding the differential characteristics of
the communication between cancer cells and the TME will open new avenues for sarcoma prognosis
and treatment.
Matrix metalloproteinases (MMP) are a group of proteolytic enzymes that mediate several of the
changes in the TME occurring during tumor development and progression [9]. In humans, 6 different
membrane-type matrix metalloproteinases (MT-MMPs) have been described. These include four
type I MT-MMPs anchored to the plasma membrane through a transmembrane domain, namely
MT1-MMP (MMP14), MT2-MMP (MMP15), MT3-MMP (MMP16), and MT5-MMP (MMP24), as well
as the glycosylphosphatidylinositol-anchored MT4-MMP (MMP17) and MT6-MMP (MMP25) [10].
MMP14 was first described by Sato et al. as a transmembrane protein which activates pro-MMP2 to
induce tumor cell invasion [11]. Most MMPs are secreted as inactive pro-proteinases that are activated
by proteolytic cleavage. Active MMP14 binds to the metallopeptidase inhibitor, tissue inhibitor of
metalloproteinases 2 (TIMP2), to form a receptor for proMMP2 activation [12,13]. MMP14 knockout
mice exhibit defects in skeletal development and angiogenesis, fibrosis of soft tissues, and premature
death. This phenotype has been attributed largely to the importance of MMP14 in collagen turnover
and bone remodeling [14,15]. While mice deficient in MMP2 exhibit relatively mild skeletal defects
which result in reduced bone mineralization and joint erosion, mutations in human MMP2 and MMP14
cause the severe connective tissue syndromes known as MONA (Multicentric Osteolysis, subcutaneous
Nodulosis, and Athropathia) and Winchester Syndrome, respectively [16–19].
MMP14 is up-regulated in several types of cancer, promoting angiogenesis, inflammation,
cancer cell invasion, and metastasis (Figure 1A) [20–23]. In genetically-modified mouse models,
MMP14 overexpression induces mammary gland adenocarcinoma formation and pancreatic
cancer development [24]. Other mouse models of epithelial cancers have also identified MMP14
expression, particularly in tumor-associated cells of the TME, to be involved in cancer progression.
An MMP14-deficient breast cancer mouse model showed reduced metastasis; an effect attributed to
the reduced collagen I degradation by stromal fibroblasts [25]. Similarly, normal mammary gland
branching depends on the expression of MMP14 by stromal but not mammary epithelial cells [26].
In addition, tumor-associated macrophages express MMP14 and are involved in matrix remodeling,
as shown in a colorectal cancer orthotopic mouse model [27]. Surprisingly, while MMP14 in the
context of cancer has mostly been investigated in epithelial tumors, its role in sarcoma remains
relatively unexplored. Yet, the MMP14 gene expression across a variety of cancer types is highest
in sarcomas, with the childhood rhabdomyosarcomas and Ewing sarcoma representing intriguing
exceptions (Figure 1B,C, www.cbioportal.org/), suggesting that it may be a particularly important
player in sarcoma biology [28,29].
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Figure 1. MMP14 expression in cancer. (A): Examples of MMP14 protein expression (in brown) in 
sarcoma (uterine sarcoma) and carcinoma (prostate carcinoma) tumors. Whereas in epithelial cancers, 
either the tumor cells or adjacent cancer associated fibroblasts can express MMP14, the mesenchymal 
sarcoma cells themselves express the protease. Arrowheads indicate high MMP14-expressing regions. 
(B): MMP14 gene expression in various cancer types based on The Cancer Genome Atlas program 
(TCGA) (www.cbioportal.org/) [28,29]. (C): MMP14 gene expression in various types of sarcoma 
(http://ist.medisapiens.com/) [30]. 
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In addition to pro-MMP2, other proteases have been identified as MMP14 substrates such as the 
zymogens pro-MMP8 and pro-MMP13 [31,32]. Moreover, MMP14 not only induces the proteolysis 
of collagen I but is also involved in the degradation of various other ECM components such as 
collagens II–IV, gelatins, fibronectin, tenascin, laminins, fibrin, vitronectin, nidogen, and aggrecan 
[33,34]. The cleavage of ECM components also leads to the release and modification of biologically 
active molecules such as growth factors and cytokines including the transforming growth factor 
(TGF)-beta [35]. Furthermore, MMP14 processes latent TGF-beta-binding protein 1 and pro-TGF-beta 
as well as soluble chemokines such as the stromal cell-derived factor (SDF)-1 and the monocyte 
chemoattractant protein (MCP)-3, having a direct effect on the immune system [36–38]. 
Processing and shedding of membrane-bound proteins is another major function of MMP14. 
Several adhesion molecules are among these proteins, including the ECM-binding integrins αv and 
α5, by which MMP14 affects cell motility [39,40]. The adhesion of integrins to fibronectin is 
modulated by tissue transglutaminase, which is an MMP14 substrate [41]. In addition, shedding of 
the ectodomain of the hyaluronic acid receptor CD44 by MMP14 induces cell migration [42,43]. Other 
membrane-anchored proteins affected by MMP14 include the low density lipoprotein receptor-
related protein (LRP), Syndecan-1, ephrin type-A receptor 2 (EphA2), the transmembrane mucin 
MUC-1, and the extracellular matrix metalloproteinase inducer (EMMPRIN), among others [44–49]. 
Moreover, MMP14 soluble form results from an autocatalytic process [10]. 
MMP14 also has non-proteolytic functions such as the TIMP2-dependent activation of the Ras-
Raf-ERK signaling cascade, which is mediated by the cytoplasmic tail of MMP14 through a process 
that involves the physical association between MMP14 and β1 integrin [50,51]. Moreover, MMP14 is 
required for lamellipodia formation and motility of myeloid progenitors, a process dependent on the 
MMP14 cytoplasmic domain, which activates the Rho GTPase Rac1 through its association with the 
i re 1. e ressi i c cer. ( ): les f r tei e ressi (i r ) i
s rc ( t ri s rc ) c rci ( r st t c rci ) t rs. r s i it li l c c rs,
it r t t r ll r j t r i t fi r l t r , t l
ll t l t t . rr s i icate high P14-expressi regio s.
:
. ( ): i
i t. i i . /) [ ].
2. Activity of MMP14
In addition to pro-MMP2, other proteases have been identified as MMP14 substrates such as the
zymogens pro-MMP8 and pro-MMP13 [31,32]. Moreover, MMP14 not only induces the proteolysis of
collagen I but is also involved in the degradation of various other ECM components such as collagens
II–IV, gelatins, fibronectin, tenascin, laminins, fibrin, vitronectin, nidogen, and aggrecan [33,34].
The cleavage of ECM components also leads to the release and modification of biologically active
molecules such as growth factors and cytokines including the transforming growth factor (TGF)-beta [35].
Furthermore, MMP14 processes latent TGF-beta-binding protein 1 and pro-TGF-beta as well as soluble
chemokines such as the stromal cell-derived factor (SDF)-1 and the monocyte chemoattractant protein
(MCP)-3, having a direct effect on the immune system [36–38].
Processing and shedding of membrane-bound proteins is another major function of MMP14.
Several adhesion molecules are among these proteins, including the ECM-binding integrins αv and α5,
by which MMP14 affects cell motility [39,40]. The adhesion of integrins to fibronectin is modulated by
tissue transglutaminase, which is an MMP14 substrate [41]. In addition, shedding of the ectodomain of
the hyaluronic acid receptor CD44 by MMP14 induces cell migration [42,43]. Other membrane-anchored
proteins affected by MMP14 include the low density lipoprotein receptor-related protein (LRP),
Syndecan-1, ephrin type-A receptor 2 (EphA2), the transmembrane mucin MUC-1, and the extracellular
matrix metalloproteinase inducer (EMMPRIN), among others [44–49]. Moreover, MMP14 soluble form
results from an autocatalytic process [10].
MMP14 also has non-proteolytic functions such as the TIMP2-dependent activation of the
Ras-Raf-ERK signaling cascade, which is mediated by the cytoplasmic tail of MMP14 through a process
that involves the physical association between MMP14 and β1 integrin [50,51]. Moreover, MMP14 is
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required for lamellipodia formation and motility of myeloid progenitors, a process dependent on the
MMP14 cytoplasmic domain, which activates the Rho GTPase Rac1 through its association with the
adaptor protein p130Cas [52]. In addition, both β1-integrin activation and Notch3 expression depend
on the MMP14 relocalization to the plasma membrane in melanoma cells upon contact with lymphatic
endothelial cells, which triggers an enhanced 3D invasive sprouting of the tumor cells [53].
3. MMP14 and the Mesenchymal Phenotype
Mesenchymal cells are characterized by the lack of apical-basal polarity, typically presenting
a spindle shape, capacity for high motility, front-rear polarity, and high ECM-remodeling capabilities.
In line with their ECM-remodeling characteristics, these cells typically express high levels of MMP14.
According to the Medisapiens database (http://ist.medisapiens.com/), mesenchymal stem cells are,
indeed, among the non-pathological cell types with highest MMP14 gene expression [30]. Moreover,
during development, cells of mesenchymal origin specifically express MMP14 [54].
The processes known as epithelial- and endothelial-to-mesenchymal transition, where epithelial or
endothelial cells acquire mesenchymal features, occur both in physiological contexts like development
and wound healing as well as in pathological processes such as cancer. The induction of
epithelial-to-mesenchymal transition (EMT), regulated by the major EMT-associated transcription
factors SNAI, TWIST, and ZEB, is accompanied by the upregulation of MMP14 expression, suggesting
a close relationship between the mesenchymal phenotype and MMP14 [10]. Furthermore, enhanced
expression of MMP14 has been reported to induce the acquisition of a mesenchymal phenotype in
cancer and during development, in part due to its function in cleaving collagen IV and laminins of the
epithelial basement membrane as well as the cell-cell junction protein E-cadherin [23,55–60].
Given the heterogeneity of sarcoma tissues, the phenotype of sarcoma cells can also vary, with cells
presenting mesenchymal, epithelial, and mesenchymal-epithelial mixed characteristics. Interestingly,
the process termed mesenchymal-to-epithelial transition (MET) has been reported in several soft tissue
sarcomas [61], but the regulation of MMP14 during this process has not yet been described. However,
during somatic reprogramming of mouse embryonic fibroblasts to pluripotency, a MET-like process
occurs together with the downregulation of MMP14 protein expression suggesting a link between
this process and MMP14 [62]. In synovial sarcoma and leiomyosarcoma, the downregulation of SNAI
transcription factors induces an epithelial phenotype [63,64]. Moreover, transcriptomic data from
the Cancer Genome Atlas program (TCGA) shows a significant correlation between the expression
of MMP14 and the transcription factors TWIST (TWIST1: r = 0.4, p = 8.31 × 10−11; TWIST2: r = 0.21,
p = 9.72 × 10−4) and SNAI (SNAI1: Pearson’s r = 0.23, p = 3.08 × 10−4; SNAI2: r = 0.21, p = 9.96 × 10−4)
in sarcomas, suggesting that MMP14 expression is coupled with the transcriptional program governing
the sarcoma phenotype. Experimentally, MMP14 overexpression in the synovial sarcoma cell line
SW982 has been shown to induce spindle shape morphology and an EMT-like phenotype, in conjunction
with enhanced cell invasiveness [65]. Together, these reports establish the tight association between
MMP14 and the mesenchymal phenotype, suggesting that MMP14 may also contribute to determining
the phenotypical characteristics of sarcomas. However, the regulatory interrelationships between
MMP14 and the EMT or MET processes remain poorly understood.
4. MMP14 in Sarcoma
4.1. Expression of MMPs in Soft Tissue Sarcomas
The use of MMP gene and/or protein as diagnostic markers has resulted in seemingly contradictory
results. Copy number alterations in sarcomas are generally rare. Only 1.3% of general soft tissue
sarcomas present gains of the MMP14 gene. However, when considering only angiosarcoma, 12.5% of
patients present increased copy numbers of this gene (www.cbioportal.org/) [28,29]. In other sarcomas,
the increased MMP14 expression is a far more common phenomenon than copy number alterations.
By comparing the MMP14 expression in tumor and matching normal tissues in a pan-sarcoma
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cohort, a general increase in MMP14 is observed in sarcomas (www.gepia.cancer-pku.cn/). Moreover,
an even more pronounced MMP14 expression is induced in both leiomyosarcoma and liposarcoma
(www.oncopression.com/).
Gene expression of MMPs in general associates poorly with disease prognosis. The gene
expression for non-membrane type, secreted MMPs, shows no association with disease-free survival
in undifferentiated pleomorphic sarcoma, liposarcoma, and synovial sarcoma, except for MMP8 and
MMP13 [66]. Moreover, no significant differences have been observed in the expression of MMP14
between non-metastatic and metastatic undifferentiated pleomorphic sarcoma (UPS) groups [67].
On the other hand, we reported that an aggressive subgroup of undifferentiated uterine sarcoma cases,
presenting the poorest survival rates of all subgroups, is characterized by high MMP14 gene and
protein expression [68].
Studies investigating the protein expression and activity of MMP14 and other MMPs, including
MMP2, have found stronger associations with disease prognosis, grade, and histopathological features.
In UPS, MMP2 and MMP9 protein expression and activity are higher in malignant tissues than in
the normal counterparts, and both the pro- and active forms of MMP2 are increased in metastatic
compared to non-metastatic patients [67]. Also in UPS, cells with pleomorphic characteristics (spindle
cells admixed with other mesenchymal elements) are associated with active MMP1 and MMP9
expression compared to tissues consisting purely of spindle cells, whereas MMP2 levels appear to
be unaffected [69]. In synovial sarcoma, MMP14 protein expression is higher in TNM stages III
and IV than in stages I and II, and the expression of MMP14 correlates with that of EMT-related
proteins such as increased N-cadherin and decreased E-cadherin. Moreover, high MMP14 expression
is mainly observed in spindle cell monophasic fibrous synovial sarcomas [65]. In synovial sarcoma
and liposarcoma, enhanced MMP2 protein also correlates with poor disease-free survival and in
liposarcoma it correlates with both tumor grade and metastasis [70]. In a cohort of various sarcoma
types as well as benign soft tissue neoplasms, MMP14 protein expression has been found to be higher
in sarcomas than in the benign tissues [71]. The levels of MMP2 in blood vessels are also lower in
benign neoplasms, and the percentage of activated MMP2 correlates with tumor size [71]. In this study,
MMP14 expression, however, does not correlate with active MMP2, although MMP14 activity or the
presence of other MMP2-modulatory proteins such as TIMP2 are not considered. The authors, thus,
argue that the high tissue expression of MMP14 may contribute to the activation of vascular MMP2,
promoting angiogenesis [71].
These studies highlight the differences between MMP14 gene and protein expression, as well
as the activity of MMP14 and MMP2, indicating that MMP14 protein level and activity are better
prognostic factors than the corresponding gene expression. This poor correlation can be explained by
the multiple post-transcriptional mechanisms that regulate the activity of MMPs (discussed below).
Moreover, understanding the cell phenotype- and tissue-specific functions of MMP14 in sarcoma will
be central to evaluate its potential as a prognostic marker or a therapeutic target.
4.2. MMP14 in Childhood Sarcomas
The most common soft tissue sarcomas occurring primarily in children or young adults are
rhabdomyosarcoma and Ewing sarcoma. Rhabdomyosarcoma is generally divided into three main
histological subtypes, the most common being embryonal, followed by alveolar and anaplastic.
Ewing sarcoma is a type of small round cell sarcoma that can originate both in bone and soft tissues and
is characterized by presenting FET-ETS gene fusions [72]. Few clinical studies have investigated the
role of MMP14 in rhabdomyosarcoma and Ewing sarcoma, which both express relatively low levels of
MMP14 as compared to other types of sarcoma (Figure 1C). However, some reports suggest that MMP14
could also be important in specific subtypes of these malignancies [73–75]. For instance, the more
aggressive alveolar rhabdomyosarcoma presents higher protein levels of both MMP14 and MMP2
than the embryonal rhabdomyosarcoma type, where both these proteases are often undetectable [73].
In Ewing sarcoma cell lines, a peculiar repertoire of MMP expression has been reported, with very
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low MMP1 and MMP3 mRNAs due to the presence of fusion proteins of promoter trans-activators
of MMPs, resulting in a drastic reduction of their transcription. However, all cell lines used in this
study expressed both MMP2 and MMP14, suggesting that MMP14 influences Ewing sarcoma cell
behavior [74]. Another piece of evidence for MMP14 activity in Ewing sarcoma is that the same cells
expressing MMP14 protein also present soluble Endoglin, a membrane coreceptor of the TGFβ family,
which is cleaved by MMP14 and associates with poor prognosis in Ewing sarcoma [75].
4.3. MMP14 in Kaposi Sarcoma
Kaposi sarcoma (KS) is an angiogenic tumor of endothelial origin arising in severely
immunocompromised individuals infected with Kaposi sarcoma herpesvirus (KSHV), the causative
agent of this cancer. Interestingly, KSHV infection of lymphatic endothelial cells grown in 3-dimensional
(3D) matrix induces endothelial-to-mesenchymal transition (EndMT), thus skewing the lymphatic
endothelial cell identity towards that of a mesenchymal cell type with enhanced invasive properties.
The upregulation of mesenchymal markers has been observed also within KS tissues in the virus-positive
tumor cells [57]. The increased cell invasion of KSHV-infected endothelial cells has been linked to the
systematically increased expression of several MMPs e.g., MMP1, MMP7, MMP13, and MMP14 [76].
MMP14, whose prominent expression is also seen in the virus-infected cells within KS tumors,
was specifically identified as a key player for the virus-induced sprouting of KSHV-infected lymphatic
endothelial cells in a 3D fibrin matrix and for the endothelial-to-mesenchymal reprogramming of
KSHV-infected lymphatic endothelial cells [57].
4.4. MMP14 in Osteosarcoma
Osteosarcomas are the most common bone tumors, mainly affecting children and adolescents.
Osteosarcomas are composed of malignant cells producing immature bone or osteoid tissue containing
primarily collagen I, which suggests that collagen remodeling might take part in the development of
these tumors [77]. Osteosarcoma cells express high levels of MMP14 mRNA, and the corresponding
protein correlates with poor prognosis in patients [78]. Moreover, high levels of EMMPRIN, an MMP14
substrate that stimulates the expression of MMPs [79], as well as the co-expression of EMMPRIN and
MMP14, predict poor prognosis [80]. The comparison of the gene expression between osteosarcoma
samples and matching normal bone tissue also reveals MMP14 as one of the most significantly
upregulated genes [81]. Clinically, an elevated MMP2/MMP9 activity ratio, but not mRNA or
protein expression, associates with poor response to chemotherapy in osteosarcoma [82]. In addition,
the destruction of bone tissue caused by osteosarcoma invasion is regulated by MMP14 activity together
with the endocytic collagen receptor uPARAP/Endo180 in osteosarcoma cells, a process that, contrary
to bone metastases of epithelial cancers, does not require osteoclast activity [83].
5. Regulation of MMP14 Expression and Activity
MMPs are enzymes that efficiently degrade the ECM. Therefore, high MMP levels may lead
to detrimental effects on tissue architecture and homeostasis. To avoid this, multiple layers of
regulation for the expression of each MMP exist, and their regulation is influenced by both intra- and
extra-cellular cues.
5.1. MMP14 Transcriptional Regulation
MMP14 expression is tightly regulated at the transcriptional and epigenetic levels (summarized in
Figure 2). The MMP14 promoter exhibits distinctive features, which render it unique compared to most
other MMPs. For instance, it lacks a TATA-box and harbors a functional, although non-conventional,
Sp1 transcription factor (TF) binding site [84]. An extensive characterization of the MMP14 promoter
points to at least five different transcription start sites (TSS) and the presence of a repressive regulatory
element located between −1200 and −385 nt upstream of the main TSS [84]. Recently we have
identified PROX1, the master regulator of lymphatic endothelial cell development and a TF involved
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in differentiation of organs such as liver, pancreas, retina, and brain [85], as the first direct repressor of
MMP14 transcription [86]. Notably, PROX1 binds to the MMP14 promoter at two specific, adjacent
regions located within the previously identified repressive regulatory region [84]. The PROX1-MMP14
axis represents a regulatory mechanism of cancer cell invasion and endothelial cell specification [86].
Amongst sarcomas, PROX1 is highly expressed in rhabdomyosarcoma, which could explain the
generally low expression of MMP14 in this sarcoma type. Moreover, in KS tumors PROX1 positive
cells do not express MMP14 and, vice versa, MMP14-expressing cells lack PROX1 expression [86].
Interestingly, KSHV-infection induces PROX1 transcriptional downregulation in lymphatic endothelial
cells [87], which can, thus, likely contribute to the prominent MMP14 expression in KS tumors.
In support of this is also our unpublished RNA-seq data, where depletion of PROX1 in KSHV-infected
lymphatic endothelial cells drives a significant increase in MMP14 transcript levels.
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of HIF2α, due to the genetic loss of the ubiquitin-ligase VHL, also display increased MMP14 levels
and higher metastatic rates [88]. Mechanistically, HIF2α, in concert with Sp1, can bind to the P14
pro oter thereby enhancing its expression and the invasiveness of cancer cells. Upon tetraspanin CD81
stimulation, MMP14 expression as well as MMP14-dependent melanoma invasion and metastasis are
increased through Akt-dependent Sp1 activation, which also support the function of Sp1 in regulating
the transcription of MMP14 [89].
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control the promoters of MMP genes couples Rb deregulation to the acquisition of metastatic properties
by cancer cells. Interestingly, this mechanis seems to be utilized also by oncoviruses. The human
papilloma virus (HPV) encodes for the E7 oncoprotein, which binds to and targets Rb for degradation
thereby activating, among others, the E2F transcription factor. Since the ectopic expression of the
E7 oncoprotein from the highly pathogenic HPV 16 strain in carcinoma cell lines upregulates the
expression of MMP9, MMP14 and M P13 [92], it is likely that this upregulation takes place through
E2F. However, whether this is the molecular mechanism driving the increased invasiveness an
metastasis of HPV-induced cervical and oropharyngeal carcinomas remains to be proven.
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MMP14 gene transcription can be regulated by different intra and extra-cellular pathological
and physiological stimuli. Cells, when embedded in 3D collagen matrices, mimicking the sarcoma
microenvironment (further discussed below), display increased levels of MMP14 [93,94]. The TF Egr1,
which levels are increased by mechanical stimulation and can thereby be recruited to the MMP14
promoter, has been identified as an MMP14 regulator in such collagenous microenvironments [93].
Another level of MMP14 regulation occurs through the DNA methylation of the MMP14 promoter
which, like 70% of the human genes annotated so far, contains CpG islands [95,96]. DNA methylation
patterns are crucial for the activity of methylation-sensitive TFs such as the MMP14 regulator Sp1.
Both during differentiation and cancer, the affinity of this TF to its consensus DNA binding sequence
can be modulated by DNA methylation [97,98].
It is becoming increasingly clear that, along with altered global gene expression, also the genomic
distribution of methylated DNA sequences (called methylome) is distorted in malignant cells compared
to that of their healthy counterparts [99]. In cancer cell lines, the methylation status of both MMP14
and MMP2 promoters is inversely correlated to their gene expression and to the cell migratory ability.
Hypermethylated MMP14 and MMP2 promoters have been found in the non-invasive MCF7 breast
cancer cell lines, whereas highly migratory glioma cells display hypomethylated promoters coupled to
high MMP14 and MMP2 expression levels [100,101].
The cancer suppressor protein kinase D1 (PKD1), a repressor of different MMPs, including MMP14,
is highly expressed in normal breast tissue, but epigenetically silenced by DNA methylation in invasive
breast cancer, where MMP14 and other MMPs are induced [102]. Moreover, PKD1 is downregulated in
invasive osteosarcoma compared to benign schwannoma, and PDK1 expression correlates with MMP
levels and cell invasiveness [103].
5.2. Post-Transcriptional Regulation of MMP14
With respect to the regulation of mRNA, various microRNAs have been found to target the MMP
encoding mRNAs, including those for MMP14, thus inhibiting their translation. Although several
microRNAs have been reported to target MMP14, their activities in sarcoma remain uninvestigated.
However, MMP14-targeting microRNAs, such as miR-193a-3p [104] and miR-133a [105] inhibit
osteosarcoma proliferation, invasion, and metastasis [106,107]. The miRNA let-7 [108] is frequently
downregulated in uterine leiomyosarcoma and Kaposi sarcoma [109,110], and the low expression
of miR-34a [111] correlates with poor survival and response to chemotherapy in Ewing’s sarcoma
patients [112].
MMPs are translated as latent zymogens containing an N-terminal prodomain that acts as
a shield for the catalytic site [113,114]. Removal of this inhibitory prodomain of MMP14 takes
place largely in the trans-Golgi network by proprotein convertases including furin and PC6 in
a membrane tethering-dependent manner [115–117]. However, alternative mechanism might also
take place, for instance, autocatalytic processing activity of the MMP14 proenzyme has been reported
in vitro [118]. In rhabdomyosarcoma, furin expression has been linked to malignancy in part due to its
function in the processing of pro-MMP14, whereas in osteosarcoma, furin inhibition leads to reduced
MMP14-dependent cell migration [119,120]. Thereafter, MMP14 intracellular trafficking to the plasma
membrane requires an active exocytosis of MMP14-containing Rab8-positive vesicles dependent on
microtubules and the motor proteins kinesins (Figure 3) [121,122].
At the cell surface, MMP14 is enriched in the invasive membrane protrusions known as
invadopodia [123]. Localization of MMP14 to these invasive structures depends on various molecules
that are essential for invadopodia formation such as cortactin, palladin, and the Rho-GTPases cdc42 and
RhoA. Furthermore, MMP14 itself has been proposed to be necessary for the formation and maturation
of these structures [124–127]. The control of MMP14 membrane expression is finely regulated by its
internalization and recycling, with numerous molecules controlling the endosome-to-plasma membrane
trafficking [128,129]. The internalization process of MMP14 is mediated by both clathrin-dependent
and caveolae-dependent endocytosis leading to its transport to lysosomal degradation or recycling
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compartments from where it can relocate to the plasma membrane [130–133]. Additionally, MMP14
can be secreted at the membrane of small extracellular vesicles [134].
MMP14 internalization is regulated by the protein kinase c-mediated phosphorylation of its
cytoplasmic tail [135]. Interestingly, a main component of caveolae, caveolin-1, has been reported
to promote MMP14-dependent pro-MMP2 activation in Ewing sarcoma cells contributing to their
metastatic potential, however, in epithelial breast cancer cells, but not in mesenchymal melanoma
cells, caveolin-1 leads to a reduced cell migration due to the decreased secretion of MMP2 and
MMP9 [136–138]. On the other hand, the membrane proteins flotillins, which form caeolin-1- and
clathrin-independent membrane invaginations [139], promote MMP14 internalization inducing its
recycling to invadopodia and ECM degradation in both high flotillin-expressing carcinoma and sarcoma
cells [140]. This function may contribute to the association of flotillins with poor prognosis in various
carcinomas and rhabdomyosarcoma [140].
Cells 2019, 8, x 9 of 24 
 
MMP14 internalization is regulated by the protein kinase c-mediated phosphorylation of its 
cytoplasmic tail [135]. Interestingly, a main component of caveolae, caveolin-1, has been reported to 
promote MMP14-dependent pro-MMP2 activation in Ewing sarcoma cells contributing to their 
metastatic potential, however, in epithelial breast cancer cells, but not in mesenchymal melanoma 
cells, caveolin-1 leads to a reduced cell migration due to the decreased secretion of MMP2 and MMP9 
[136–138]. On the other hand, the membrane proteins flotillins, which form caeolin-1- and clathrin-
independent membrane invaginations [139], promote MMP14 internalization inducing its recycling 
to invadopodia and ECM degradation in both high flotillin-expressing carcinoma and sarcoma cells 
[140]. This function may contribute to the association of flotillins with poor prognosis in various 
carcinomas and rhabdomyosarcoma [140]. 
 
Figure 3. The plasma membrane expression of MMP14 is highly regulated. After translation, MMP14 
is an inactive zymogen containing an inhibitory pro-domain that is cleaved in the Trans-Golgi 
Network by proprotein convertases (i.e., furin). Thereafter, MMP14 is transported to invadopodia, 
actin-rich protrusions with high matrix degradation capabilities, through microtubules. 
Internalization of MMP14 occurs via clathrin-, flotillin-, and/or caveolin 1-dependent endocytosis. The 
internalized MMP14 is then stored in late and recycling endosomes, where it can be re-directed to the 
plasma membrane, or degraded in lysosomes. 
5.3. MMP14 Regulation at the Membrane 
The activity of MMPs at the plasma membrane is constantly regulated by the endogenous tissue 
inhibitors of metalloproteinases TIMPs, which reversibly bind to MMPs in a 1:1 stoichiometry [141]. 
There are four members of TIMPs (TIMP1-4) in humans, which show tissue-specific expression [142]. 
The balance between TIMP and MMP expression is important to maintain normal tissue homeostasis 
and is often dysregulated in cancer. TIMP2-4, but not TIMP1, are strong inhibitors of MMP14 [143]. 
TIMP2 forms a complex with pro-MMP2 that is recognized by one molecule of the MMP14 
homodimer allowing the activation of pro-MMP2 by the second molecule of MMP14 [144–147]. Thus, 
Figure 3. The plasma membrane expression of MMP14 is highly regulated. After translation, MMP14
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by proprotein convertases (i.e., furin). Thereafter, MMP14 is transported to invadopodia, actin-rich
protrusions with high matrix degradation capabilities, through microtubules. Internalization of MMP14
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then stored in late and recycling endosomes, where it can be re-directed to the plasma membrane,
or degraded in lysosomes.
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There are four members of TIMPs (TIMP1-4) in humans, which show tissue-specific expression [142].
The balance between TIMP and MMP expression is important to maintain normal tissue homeostasis
and is often dysregulated in cancer. TIMP2-4, but not TIMP1, are strong inhibitors of MMP14 [143].
TIMP2 forms a complex with pro-MMP2 that is recognized by one molecule of the MMP14 homodimer
allowing the activation of pro-MMP2 by the second molecule of MMP14 [144–147]. Thus, although
TIMP2 is important for pro-MMP2 activation, an excess of TIMP2 would inhibit both MMP14 molecules.
Gene expression ofTIMP2 in sarcomas is generally high. In Ewing sarcoma and rhabdomyosarcoma,
however, TIMP2 follows a similar pattern of low expression, as with MMP14. Interestingly, MMP2 and
MMP14 genes are the first and third most significantly co-expressed genes with TIMP2 in sarcoma
(TCGA-SARC) indicating that these genes share common regulation mechanisms. Gene expression
of TIMP4 is low in sarcomas except for liposarcoma. Moreover, the general expression of TIMP2 is
upregulated in sarcomas compared to normal tissue (http://gepia.cancer-pku.cn). This upregulation
has been specifically reported in alveolar soft-part sarcoma and chondrosarcoma [148,149]. At the
protein level, TIMP2 expression correlates with that of MMP2 and MMP14 in chondrosarcoma, all three
proteins displaying elevated levels in high-grade anaplastic components compared to low-grade
components of de-differentiated and conventional chondrosarcoma [150]. In synovial sarcoma, however,
low expression of TIMP2 is a poor prognostic factor for disease-free survival [70]. TIMP4 expression in
turn is relatively high in well-differentiated liposarcoma and low in the more aggressive undifferentiated
liposarcoma, whereas TIMP1 shows an opposite expression pattern in these sarcomas. The switch
from well-differentiated to undifferentiated phenotypes occurring at low TIMP4 and high TIMP1 levels
has been attributed to the activation of the oncogenes yes-associated protein (YAP) and transcriptional
co-activator with PDZ binding motif (TAZ), which have also been associated with sarcomagenesis and
maintenance of stem cell-like features in various cancer types [151–153].
MMP14 activity can also be inhibited by other proteins. Reversion-inducing-cysteine-rich
protein with kazal motifs (RECK) is a membrane-anchored inhibitor of MMP14 [154]. In addition,
testican 3 and N-Tes (a splicing variant of testican 3) have inhibitory effects on MMP14 and MMP2
activation [155]. On the other hand, the tight junction proteins claudins have been shown to induce
MMP14-dependent activation of pro-MMP2 independently of TIMP2, a process not restricted to the
cell–cell border [156,157]. Tight junctions are typically formed in epithelial and endothelial cells,
but some sarcoma cells including synovial sarcoma and osteosarcoma as well as osteoblasts form these
structures [158–160]. De-localization of claudin-1 from tight junctions has been observed in metastatic
osteosarcoma cells [160], suggesting its involvement in metastasis could be linked to MMP14 activity.
5.4. ECM Biomechanics and Dimensionality Affect MMP14
ECM stiffness has been linked to aggressiveness and EMT in various cancer cell types, and sensors
of the mechanical properties of the ECM such as integrins are important players in MMP14-mediated
cell invasion in 3D microenvironments [161]. Several studies have investigated the effects of ECM
stiffness on MMP14 expression and activity. However, most of the models used to date consist of
stiffness-controlled 2D substrates. These studies, which include carcinoma cells and mesenchymal
cells, fail to show a clear link between stiffness and MMP14 gene expression and activity [94,162–166].
The observed variability may be explained by the uncoupling of ECM stiffness and MMP14 activity
in cancer. This deregulation has been reported when comparing endometrial stromal cells and
endometriotic stromal cells, where the former show enhanced MMP14 gene expression with substrate
stiffness but the latter are unresponsive [166]. Moreover, in carcinoma cells, substrate stiffness has been
linked to EMT, which could lead to indirect changes in MMP14 expression [167].
The activity of MMP14 is highly relevant in 3D environments where physical constrictions impede
the free migration of cells. Moreover, the expression and activity of MMP14 is enhanced when cells are
in 3D matrices compared with 2D, even when the stiffness of these are comparable, an increase that
was reported to be independent of β1-integrin binding with the ECM [94]. Most models that have
been used to study the function of MMP14 in 3D microenvironments have used collagen matrices of
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various concentrations and crosslinking conditions. However, these models do not systematically
control pore size, integrin ligand density, and collagen fiber mechanical properties, all factors that
can potentially affect MMP14. Thus, the use of engineered matrices controlling integrin ligand and
cleavable site density, as well as porosity and mechanical properties will shed light on the regulation of
MMP14 by the different factors independently.
Recent studies have shown that both force- and MMP-dependent matrix remodeling regulate
confined cell migration and cell phenotype, indicating that both mechanical and biochemical properties
of the cellular milieu affect cell behavior [168,169]. These effects could be involved in the relationship
between MMP14 expression and the mesenchymal phenotype, where changes in cell confinement and
the ability to remodel the ECM as a result of MMP14 activity could lead to phenotypical changes in
sarcoma cells.
6. Sarcoma Metastasis and MMP14
Cancer cell dissemination and colonization of distant organs coupled to therapy resistance is the
main cause of mortality associated to cancer. Dissemination of sarcoma cells from the primary tumor to
secondary sites occurs through three main distinct routes, the vascular system, the lymphatic system,
or directly into tissues and body cavities. The unique relationship between sarcoma cells and their
milieu is fundamental to understand the characteristic metastatic process of these cells, with MMPs
playing a central role [9].
6.1. ECM Architecture and MMP14 in Cell Migration
To initiate the metastatic process, sarcoma cells dissociate from the primary tumor, gaining the
ability to invade benign/stromal tissues. Cancer cells can use various modes of migration to invade
their surroundings depending on their cell/tissue of origin and phenotype as well as the characteristics
of their microenvironment. Cells migrate through the ECM by remodeling it, opening migration
tracks or by using pre-existing tracks [170]. When pore-like migration tracks are too small for a cell
to move through, proteolytic degradation of the ECM is often required [171]. In vitro studies show
that fibrosarcoma HT-1080 cells embedded in high-density collagen matrices, which have small pores,
induce collective migration, a migration type that consists of cells invading together following initial
leader cells [172]. This process is dependent on the MMP-mediated proteolytic collagen breakdown.
Although MMP14 is required for HT-1080 cell migration in dense collagen matrices, the directionality of
their migration is driven by the fibrillar topography of the ECM independently of MMP14, which further
indicates the strong effect of the ECM architecture on cell migration [173].
Recently, several models have been proposed to explain the mechanisms governing mesenchymal
cell migration in dense collagen matrices. Regarding collective cell migration, a study using
fibrosarcoma HT-1080 cells shows that these cells present an anterior force-generating leading edge
containing β1-integrin, F-actin, and MMP14 responsible for the re-alignment of collagen fibers into
microtracks, which cells use to migrate. The following cells also use these tracks and further widen
them, as they are the sites of least confinement, resulting in collective migration [161] (Figure 4A).
A second study links cell migration in confined microenvironments with localized MMP14-dependent
collagenolysis and the cell nucleus (Figure 4B). A limiting factor in confined migration, where the
diameter of pores is smaller than that of the nucleus, is the capacity of the nucleus to deform [174].
In migrating mesenchymal cells, MMP14-containing storage endosomes become polarized in front of
the nucleus in the direction of cell migration and their positioning depends on the function of the linker
of nucleoskeleton and cytoskeleton (LINC) complex in connecting the nucleus and the centrosome [175].
Therefore, the nucleus can act as a sensor of the ECM architecture to direct collagenolysis. Nuclear
deformation depends on its stiffness and, interestingly, loss of MMP14 causes alterations of the
nuclear envelope and nuclear softening, further indicating a relationship between MMP14 and the
nucleus [176].
Cells 2019, 8, 991 12 of 24
Cells 2019, 8, x 12 of 24 
 
 
Figure 4. The structure and mechanical properties of the ECM, as well as MMP14 activity can all affect 
the mode of 3D cell migration. (A): Mesenchymal cells embedded in a dense 3D collagen matrix 
migrate collectively due to the formation of microtracks initiated by the MMP14-dependent 
collagenolysis first induced by leader cells. (B): In mesenchymal cells migrating in matrices with small 
pores (confined environment), MMP14-rich endosomes are polarized in front of the nucleus to direct 
the matrix degradation pericellularly towards the direction of the migration enabling the formation 
of pores wider than the cell nucleus. This endosome polarization depends on the LINC complex and 
the positioning of the centrosome ahead of the nucleus. (C): The type of 3D cell migration depends on 
characteristics of the matrix such as pore size and its elasticity and plasticity but also depend on 
cellular features such as the activity of MMP14, and that of the Rho GTPases Rac1, cdc42 impacting 
on the formation of invadopodia and matrix degradation, and RhoA inducing myosin II-dependent 
contractility. 
The mode of migration used by mesenchymal cells is determined by both the structural and 
mechanical characteristics of the matrix, and by the ability of cells to remodel it (Figure 4C). Matrix 
degradation is not required for mesenchymal migration when the pore size of the matrix is large and 
when the matrix is mechanically plastic, which allows cells to deform it by applying force [169]. This 
type of migration is characterized by the formation of large protrusions at the leading cell edge called 
lamellipodia or by invadopodia. On the other hand, inhibition of MMP activity in HT-1080 cells 
embedded in dense 3D matrices causes decreased adhesion and increased actomyosin activity, 
leading to cell rounding and a switch of the migration type to ameboid [177]. Healthy primary 
fibroblasts switch their migration type from lamellipodial to a high pressure lobopodial-forming type 
in highly crosslinked collagen matrices. Lobopodial migration occurs in matrices presenting linear 
elasticity and in cells with high RhoA-ROCK-myosin II activity [178]. Similarly, fibrosarcoma HT-
1080 and SW684 cells switch to a high-pressure lobopodial migration after MMP pharmacological 
inhibition. This migration mode depends on integrin adhesion, actomyosin contractility, and the 
LINC complex protein Nesprin-3 [179]. Altogether, these studies demonstrate the dependence of 
mesenchymal cells on MMP14 activity and the physical characteristics of the extracellular milieu to 
determine the mode of migration. 
Figure 4. The structure and mechanical properties of the ECM, as well as MMP14 activity can all
affect the mode of 3D cell migration. (A): Mesenchymal cells embedded in a dense 3D collagen
matrix migrate collectively due to the formation of microtracks initiated by the MMP14-dependent
collagenolysis first induced by leader cells. (B): In mesenchymal cells migrating in matrices with
small pores (confined environment), MMP14-rich endosomes are polarized in front of the nucleus
to direct the mat ix degradation pericellularly towards the directio of the migrati n enabling the
formation of pores wider than th cell nucleus. Thi endosome p larization depe s o the LINC
complex nd the p sitioning of the centrosome ahead of the nucleus. (C): The type of 3D cell migration
depends on characteristics of the matrix such as pore size and its elasticity and plasticity but also
depend on cellular features such as the activity of MMP14, and that of the Rho GTPases Rac1, cdc42
impacting on the formation of invadopodia and matrix degradation, and RhoA inducing myosin
II-dependent contractility.
The mode of migration used by mesenchymal cells is determined by both the structural and
mechanical characteristics of the matrix, and by the ability of cells to remodel it (Figure 4C). Matrix
degradation is not required for mesenchymal migration when the pore size of the matrix is large
and when the matrix is mechanically plastic, which allows cells to deform it by applying force [169].
This type of migration is char cterized by th formation of large protrusions a the leading cell edge
called lamellipodia or by i v dopodia. On the other hand, inhibition of MMP activity in HT-1080 cells
embedded in dense 3D matrices causes decreased adhesion and increased actomyosin activity, leading
to cell rounding and a switch of the migration type to ameboid [177]. Healthy primary fibroblasts
switch their migration type from lamellipodial to a high pressure lobopodial-forming type in highly
crosslinked collagen matrices. Lobopodial migration occurs in matrices presenting linear elasticity
and in cells with high RhoA-ROCK-myosin II activity [178]. Similarly, fibrosarcoma HT-1080 and
SW684 cells switch to a high-pressure lobopodial migration after MMP pharmacological inhibition.
This migration mode depends on integrin adhesion, actomyosin contractility, and the LINC complex
protein Nesprin-3 [179]. Altogether, these studies demonstrate the dependence of mesenchymal cells
on MMP14 activity and the physical characteristics of the extracellular milieu to determine the mode
of migration.
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6.2. MMP14 and the Vascular Metastatic Route
Contrary to carcinomas, which actively metastasize to lymph nodes via lymphatic vessels
(lymphogenous route), sarcomas primarily spread through blood vessels (hematogenous route), except
for epithelioid sarcoma, clear cell sarcoma, angiosarcoma, and alveolar rhabdomyosarcoma [180,181].
Subsequently, the hematogenously spreading soft tissue sarcomas and osteosarcoma predominantly
metastasize to the lungs [182,183].
Knock-down of MMP14 in triple negative breast cancer cells, which have a mesenchymal
phenotype, reduces blood vessel invasion but not lymphatic vessel invasion. Moreover, MMP14
expression in cancer cells induces the expression of MMP14 in blood but not in lymphatic endothelial
cells [184]. Downregulation of MMP14 also reduces the formation of lung metastases without affecting
primary tumor size in a mouse model of breast cancer [185]. Furthermore, collectively migrating
cells, but not singly-migrating cells, are restricted to lymphatic invasion [185]. In line with these
observations, we reported that reduction of MMP14 membrane expression caused by MMP16, the other
MT-MMP frequently expressed in sarcomas (http://ist.medisapiens.com/) forming complexes with
MMP14 [186], promotes collective migration in melanoma cells that preferentially invade lymphatic
vessels [187]. This suggests that MMP14 and a mesenchymal-like single cell migration facilitates the
blood vessel invasion of these cells. Although mechanistic studies on the preference for sarcoma cells
to use the hematogenous over the lymphogenous route, and to metastasize in the lungs, are lacking,
the mesenchymal characteristics and the high MMP14 expression of these tumors might explain the
intravasation into blood vessels. Moreover, the low MMP14 expression of alveolar rhabdomyosarcomas
and the epithelial characteristics of epithelioid sarcomas is consistent with their preference for utilizing
the lymphogenous route.
7. Clinical Implications and Future Perspectives
Matrix metalloproteases, including MMP-14, are attractive therapeutic target candidates due to
central functions in numerous diseases, as well as their principally druggable cell surface or extracellular
activities. However, more than 50 MMP inhibitors have been investigated in various clinical trials
without success [188]. Several small molecule inhibitors of MMP14 have been developed, but so far
none of them has succeeded in clinical trials. The failure of these clinical trials has been attributed to
several factors, such as the biological complexity of the MMP function or the inhibitors themselves, as
well as poor trial design with inadequate clinical endpoints. There are, however, ongoing attempts to
develop new, more precisely targeted, MMP inhibitors. For example, novel inhibitory anti MMP14
antibodies have been recently developed and used in cell lines and primary xenograft assays to limit
hypoxia, immune suppression, and metastasis [189]. Another recent study has demonstrated efficacy
of targeting the MMP14/MMP2/integrin αvβ3 axis using protein monomers and heterodimers that
bind to both MMP14 and integrin αvβ3 [190]. These studies demonstrate that interest in therapeutic
targeting of MMP14 continues.
Understanding the specific alterations and functions of MMP14 and its regulation in sarcomas
can open new opportunities to find targetable candidates to inhibit sarcoma invasion and metastasis.
However, as seen in pediatric sarcomas, MMP14 expression is not necessary for sarcoma development
and progression, and its inhibition in high MMP14-expressing sarcomas may not be effective to
block sarcoma cell dissemination or disease progression. This could be due to the activation of
alternative mechanisms of cancer invasion and metastasis [177,179]. Investigating the differences
between low- and highly-expressing MMP14 sarcoma types in invasion and metastasis will shed
light on these questions. Moreover, as the ECM characteristics influence cell behavior and MMP14
activity, targeting ECM changes occurring during tumor development, a process known as ECM
normalization, could be beneficial for these patients. Currently, several promising ECM-normalizing
and mechanotransduction-targeting drugs are in clinical trials, thus, it will be of interest to investigate
whether these affect MMP14 function as part of their mechanisms of action [191]. Furthermore,
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the changes in the ECM occurring during development and aging could be involved in the strong
differences observed between pediatric and adult sarcomas [192].
In terms of use as a biomarker, the biomarkers that achieve most clear breakthrough into
diagnostics are typically those related to a specific therapy. This bar is high and has yet to be met by
MMP14. Further studies are required to conclude whether MMP14 overexpression alone, or possibly in
combination with markers of ECM alterations or other MMP14 target proteins, may indicate particular
tumor subtypes that could then be treated with a more molecular-based therapy. Considering the poor
correlation between MMP14 gene and protein expression and its activity, the potential of using the
active form of MMP14 or its effectors as biomarkers should also be further explored. Additionally,
as MMP14 function is highly regulated by the microenvironment, active MMP14 quantification should
preferentially be performed within the native tissue context. To meet this need, several fluorescent and
bioluminescent probes have been developed [193]. The use of these probes and novel MMP activity
reporter constructs will facilitate the investigation of the relationship between MMP14 and the tumor
microenvironment in vivo [194].
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